11β-hydroxylase deficiency epidemiology and demographics

Revision as of 20:26, 26 January 2016 by Ammu Susheela (talk | contribs)
Jump to navigation Jump to search

Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

11β-hydroxylase deficiency epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of 11β-hydroxylase deficiency epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on 11β-hydroxylase deficiency epidemiology and demographics

CDC on 11β-hydroxylase deficiency epidemiology and demographics

11β-hydroxylase deficiency epidemiology and demographics in the news

Blogs on 11β-hydroxylase deficiency epidemiology and demographics

Directions to Hospitals Treating Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency

Risk calculators and risk factors for 11β-hydroxylase deficiency epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Overview

Epidemiology and Demographics

Prevalence

The prevalence of congenital adrenal hyperplasia due to 11β-hydroxylase deficiency in United States is approximately 1 per 100,000 individuals.

Incidence

CAH due to 11-beta-hydroxylase deficiency accounts for 5 to 8 percent of all cases of congenital adrenal hyperplasia. It is estimated that CAH due to 11-beta-hydroxylase deficiency occurs in 1 in 100,000 to 200,000 newborns. This condition is more common in Moroccan Jews living in Israel, occurring in approximately 1 in 5,000 to 7,000 newborns

Case Fatality Rate

Age

Gender

  • Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency affects male and female equally.

Race

  • Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency usually affects individuals of the Jewish race.

Developed Countries

Developing Countries

References


Template:WikiDoc Sources